Abstract:The role of circulating extracellular vesicles in cancer biology is an area of intense research interest. Here, we reveal a tumor suppressor mechanism of HD-PTP (His Domain Protein Tyrosine Phosphatase, encoded by PTPN23), a protein associated with ESCRT (endosomal sorting complex required for transport), a complex that controls endosome sorting and exosome secretion. While loss of HD-PTP is known to be tumorigenic in mice and is frequently observed in human cancers including Triple Negative Breast Cancer (TNBC), the relevant pathways have remained obscure. We find that inhibition of HD-PTP in vivo promotes tumor progression selectively in a syngeneic, immune-competent TNBC model but not in a matched immune-deficient model. Through systematic profiling of the exosomal proteome in HD-PTP proficient and deficient cells, we identify PD-L1 as a key exosomal cargo selectively enriched due to loss of HD-PTP. Mechanistically, we show that inhibition of HD-PTP results in PD-L1 stabilization, its co-localization with the exosomal marker CD63, the enrichment of endosomal PD-L1 and subsequent increase in ExoPD-L1 release. Exosomes produced post HD-PTP loss inhibits antigen-dependent T cell activity in vitro, and HD-PTP inhibition in a syngeneic TNBC model promotes non-cell-autonomous, exosome- and PD-L1-dependent tumor progression, associated with reduced T cell infiltration and altered macrophage polarization. Consistent with these findings, low HD-PTP levels in human solid tumors are associated with decreased tumor infiltrating lymphocytes, poor response to immune checkpoint inhibition and inferior overall survival. Taken together, our studies unveil a novel tumor suppressor pathway controlling PD-L1 trafficking and ExoPD-L1 secretion, highlighting the critical roles of HD-PTP and ESCRT in anti-tumor immunity. Citation Format: Chenxu Guo, Sheng Sun, Nayana Thimmiah, Agustina Maccio, Siang Koh, Leif Ellisen. HD-PTP mediates tumor suppression via modulation of anti-tumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3015.

From Nuclear to Extracellular PTEN: Multiple Roles in Tumor Suppression and Immune Modulation

Secreted PTEN binds PLXDC2 on macrophages to drive antitumor immunity and tumor suppression

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

The regulation of PTEN: Novel insights into functions as cancer biomarkers and therapeutic targets

PTENα functions as an immune suppressor and promotes immune resistance in PTEN-mutant cancer

The functions of tumor suppressor PTEN in innate and adaptive immunity

Decoding PTEN: from biological functions to signaling pathways in tumors

PTEN in Chromatin Remodeling.

PTENless means more.

Regulation of the tumor suppressor PTEN by natural anticancer compounds

Abstract 3015: HD-PTP mediates tumor suppression via modulation of anti-tumor immunity

The functions and regulation of the PTEN tumour suppressor: new modes and prospects

Abstract LB-24: C-terminal PTEN is Essential for Maintenance of Genomic Stability and Tumor Suppression

PTENε Suppresses Tumor Metastasis Through Regulation of Filopodia Formation.

Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?

PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism

PTEN Deficiency Facilitates Exosome Secretion and Metastasis in Cholangiocarcinoma by Impairing TFEB-mediated Lysosome Biogenesis

A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development

PTEN C-terminal Deletion Causes Genomic Instability and Tumor Development.

PTEN Nuclear Localization is Regulated by Oxidative Stress and Mediates P53-Dependent Tumor Suppression